Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Risk Factors and Prediction Model for Long-Term Survival of Ⅲ-Ⅵ Steroid-Refractory Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Yaxue Wu, Xiaohui Hu, Depei Wu, Shanshan Jiang, Yuanbing Wu

Blood (2024) 144 (Supplement 1): 7360.

https://doi.org/10.1182/blood-2024-203523

Published: 2024

Journal Articles

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Blood (2024) 144 (Supplement 1): 971.

https://doi.org/10.1182/blood-2024-202801

Published: 2024

Journal Articles

Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia

Ziyu Feng, Xiaohui Hu, Weiyang Li, Ting Xu, Yang Xu, Shengli Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Suning Chen, Aining Sun, Depei Wu, Ying Wang

Blood (2024) 144 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2024-198648

Published: 2024

Journal Articles

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Jing Lu, Shengli Xue, Ying Wang, Hai-Ping Dai, Xuefeng He, Xiaohui Hu, Miao Miao, Huiying Qiu, Han Yue, Caixia Li, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 970.

https://doi.org/10.1182/blood-2023-181347

Published: 2023

Journal Articles

Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study

Jing Lu, Ying Wang, Huiying Qiu, Xin Zhou, Xuzhang Lu, Miao Miao, Bin Gu, Xiaohui Hu, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 4243.

https://doi.org/10.1182/blood-2023-174831

Published: 2023

Journal Articles

Maintenance Therapy with Chidamide Plus Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia Patients

Xiaohui Hu, Depei Wu, Suning Chen, Yaxue Wu, Yang Zhang, Lian Bai, Bing Wu, Haixia Zhou, Mingzhu Xu, Shanshan Jiang, Chongsheng Qian, Shengli Xue

Blood (2023) 142 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2023-182570

Published: 2023

Journal Articles

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Blood (2023) 142 (15): 1323–1327.

https://doi.org/10.1182/blood.2023020102

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Jundan Xie, Xiaofei Yang, Xiebing Bao, Hongjie Shen, Jiannong Cen, Li Yao, Xiaohui Hu, Qian Wu, Jingren Zhang, Xuefeng He, Xiaowen Tang, AiNing Sun, Hongchun Qiu, Shengli Xue, Ying Wang, Jianhong Fu, Huiying Qiu, Depei Wu, Suning Chen

Blood (2022) 140 (Supplement 1): 1439–1440.

https://doi.org/10.1182/blood-2022-166384

Published: 2022

Journal Articles

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Suning Chen, Jundan Xie, Xiaofei Yang, Hongjie Shen, Jiannong Cen, Li Yao, Xiaohui Hu, Qian Wu, Jingren Zhang, Hongchun Qiu, Xiaowen Tang, Aining Sun, Shengli Xue, Ying Wang, Huiying Qiu, Depei Wu

Blood (2021) 138 (Supplement 1): 35.

https://doi.org/10.1182/blood-2021-153288

Published: 2021

Journal Articles

Outcome Of Dose-Adjusted Decitabine Regimen Compared With FLAG Regimen In The Treatment Of Relapsed/Refractory Acute Myeloid Leukemia

Qian Wu, Guangsheng He, Wu Depei, Aining Sun, Huiying Qiu, Zhengming Jin, Miao Miao, XiaoWen Tang, MD, Yue Han, Yiming Shen, Feng Chen, Xiaohui Hu, Song Jin, Xuhui Zhang

Blood (2013) 122 (21): 5031.

https://doi.org/10.1182/blood.V122.21.5031.5031

Published: 2013

Journal Articles

A Novel Therapy Of HLA-Mismatched Sibling Donor Combined With Third-Party Single Cord Blood Cell Transplantation In Patients With Hematologic MalignanciesÂFimproved Outcome Compared To Conventional Transplantation

Aining Sun, Shuo Yang, Jun Wang, Xiao Ma, Weiyang Li, Xiaohui Hu, Huiying Qiu, Wu Depei

Blood (2013) 122 (21): 2088.

https://doi.org/10.1182/blood.V122.21.2088.2088

Published: 2013

Journal Articles

Changes of ADAMTS13 Activity and VWF Level in the Plasma of Patients Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)

Yue Han, Luping HU, Qian Zhu, Yang Xu, Xiaohui Hu, Jian Su, Zhenni Ma, Wei Zhang, Aining Sun, Huiying Qiu, Zhaoyue Wang, MD, Changgeng Ruan, MD, PhD, Wu Depei

Blood (2012) 120 (21): 3329.

https://doi.org/10.1182/blood.V120.21.3329.3329

Published: 2012

Journal Articles

Umbilical Cord-Derived Mesenchymal Stem Cells for Treatment of Steroid-Resistant Severe Acute Graft-Versus-Host Disease

Guanghua Chen, MD, Ting Yang, Chengcheng Fu, Miao Miao, Zhengming Jin, XiaoWen Tang, MD, Yue Han, Guangsheng He, Xuhui Zhang, Xiao Ma, Feng Chen, Xiaohui Hu, Shengli Xue, Ying Wang, Huiying Qiu, Aining Sun, Wu Depei, MD, PhD

Blood (2011) 118 (21): 4536.

https://doi.org/10.1182/blood.V118.21.4536.4536

Published: 2011

Journal Articles

Risk Factors and Clinical Outcome of Thrombotic and Bleeding Complications in 527 Patients Following Hematopoietic Stem-Cell Transplantation (HSCT)

Yue Han, Wu Depei, MD, PhD, Luping Hu, Yongya Ren, Aining Sun, Huiying Qiu, Xiaohui Hu, Ying Wang, Xiaojin Wu, Wei Zhang, Zhaoyue Wang, Changgeng Ruan

Blood (2011) 118 (21): 3076.

https://doi.org/10.1182/blood.V118.21.3076.3076

Published: 2011

Journal Articles

Novel Therapy with Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

XiaoWen Tang, MD, Qianlan Zhou, Zhengming Jin, Chengcheng Fu, Chunmei Ye, Xiaolan Shi, Xiaohui Hu, Biyun Peng, Fan Ye, Yuxia Lu, Ziling Zhu, Yufeng Feng, Huirong Chang, Aining Sun, Wu Depei, MD, PhD

Blood (2011) 118 (21): 658.

https://doi.org/10.1182/blood.V118.21.658.658

Published: 2011

Journal Articles

Retrospective Investigation of Hemostatic Complications In 423 Patients Receiving Hematopoietic Stem-Cell Transplantation (HSCT).

Yue Han, Wu Depei, MD, PhD, Luping Hu, Lili Zhou, Yongya Ren, Wei Zhang, Xiaojin Wu, Xiaohui Hu, Xiang Zhang, Zhaoyue Wang, Changgeng Ruan, MD, PhD

Blood (2010) 116 (21): 4505.

https://doi.org/10.1182/blood.V116.21.4505.4505

Published: 2010

Journal Articles

Bortezomib and High-Dose Melphalan as a Novel Conditioning Regimen for Patients with POEMS Syndrome Undergoing Autologous Peripheral Blood Stem Cell Transplantation.

XiaoWen Tang, MD, Xiaolan Shi, Xiaohui Hu, Shengli Xue, Huiying Qiu, Yue Han, Lingzhi Yan, Huifen Zhou, Yuejun Liu, Bin Gu, Aining Sun, Wu Depei, MD, PhD

Blood (2010) 116 (21): 4599.

https://doi.org/10.1182/blood.V116.21.4599.4599

Published: 2010

Journal Articles

Effect Analysis of Antithymocyte Globulin Versus Antilymphocyte Globulin for Graft Versus Host Disease Prophylaxis in 102 Cases of Allogeneic Hematopoitic Stem Cell.

Chengcheng Fu, Shiqiang Qu, Wu Depei, Aining Sun, Zhengming Jin, Huiying Qiu, Weirong Chang, Xiaowen Tang, Miao Miao, Xiao Ma, Ying Wang, Shengli Xue, Ye Zhao, Yuejun Liu, Xiaohui Hu, Xiuli Wang, Xiaojin Wu

Blood (2009) 114 (22): 4325.

https://doi.org/10.1182/blood.V114.22.4325.4325

Published: 2009

NARROW

Risk Factors and Prediction Model for Long-Term Survival of Ⅲ-Ⅵ Steroid-Refractory Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study

Maintenance Therapy with Chidamide Plus Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia Patients

Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Outcome Of Dose-Adjusted Decitabine Regimen Compared With FLAG Regimen In The Treatment Of Relapsed/Refractory Acute Myeloid Leukemia

A Novel Therapy Of HLA-Mismatched Sibling Donor Combined With Third-Party Single Cord Blood Cell Transplantation In Patients With Hematologic MalignanciesÂFimproved Outcome Compared To Conventional Transplantation

Changes of ADAMTS13 Activity and VWF Level in the Plasma of Patients Undergoing Hematopoietic Stem-Cell Transplantation (HSCT)

Umbilical Cord-Derived Mesenchymal Stem Cells for Treatment of Steroid-Resistant Severe Acute Graft-Versus-Host Disease

Risk Factors and Clinical Outcome of Thrombotic and Bleeding Complications in 527 Patients Following Hematopoietic Stem-Cell Transplantation (HSCT)

Novel Therapy with Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Retrospective Investigation of Hemostatic Complications In 423 Patients Receiving Hematopoietic Stem-Cell Transplantation (HSCT).

Bortezomib and High-Dose Melphalan as a Novel Conditioning Regimen for Patients with POEMS Syndrome Undergoing Autologous Peripheral Blood Stem Cell Transplantation.

Effect Analysis of Antithymocyte Globulin Versus Antilymphocyte Globulin for Graft Versus Host Disease Prophylaxis in 102 Cases of Allogeneic Hematopoitic Stem Cell.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only